In patients infected with human immunode¢ciency virus type 1 (HIV-1), a large amount of virus is associated with follicular dendritic cells (FDCs) in lymphoid tissue. To assess the in£uence of FDCs on viral dynamics during antiretroviral therapy, we have developed a mathematical model for treatment of HIV-1 infection that includes FDCs. Here, we use this model to analyse measurements of HIV-1 dynamics in the blood and lymphoid tissue of a representative patient, who was treated with a combination of HIV-1 reverse transcriptase and protease inhibitors. We show that loss of virus from FDCs during therapy can make a much larger contribution to plasma virus than production of virus by infected cells. This result challenges the notion that long-lived infected cells are a signi¢cant source of HIV-1 during drug therapy. Due to release of FDC-associated virus, we ¢nd that it is necessary to revise upward previous estimates of c, the rate at which free virus is cleared, and¯, the rate at which productively infected cells die. Furthermore, we ¢nd that potentially infectious virus, present before treatment, is released from FDCs during therapy and that the persistence of this virus can be a¡ected by whether therapy includes reverse transcriptase inhibitors.
INTRODUCTION

Follicular dendritic cells (FDCs) in lymphoid tissue (LT)
play an important role in the pathogenesis of human immunode¢ciency virus type 1 (HIV-1) (Pantaleo et al. 1994) . The amount of virus associated with these cells exceeds the amount in blood by an order of magnitude or more (Haase et al. 1996) . A large pool of FDC-associated virus is present even early in infection before seroconversion (Schacker et al. 2000) . When one considers the amount of virus in the FDC network and the rapid loss of FDC-associated virus during treatment with HIV-1 reverse transcriptase (RT) and protease inhibitors (Cavert et al. 1997; Wong et al. 1997; Stellbrink et al. 1997; Tenner-Racz et al. 1998; Orenstein et al. 1999) , it is conceivable that FDCs have the potential to in£uence HIV-1 dynamics during antiretroviral therapy. Moreover, the FDC pool of virus may be able to perpetuate infection, as FDC-associated virus is highly infectious (Heath et al. 1995) and may remain infectious for long periods (Burton et al. 1997) .
Because RT and protease inhibitors have no direct e¡ect on viral clearance, Cavert et al. (1997) proposed that free and FDC-associated virus are in dynamic equilibrium before treatment and that loss of virus is due to dissociation, with treatment causing a net loss of FDCassociated virus by reducing the pool of free virus available for binding to FDC. Hlavacek et al. (1999) developed a physicochemical model for the binding of HIV-1 to receptors on FDCs and showed that reduction of free virus and reversible multivalent ligand^receptor interactions can plausibly account for the dynamics of FDCassociated viral decay during therapy, including the observed pattern of biphasic decay (Cavert et al. 1997) . In previous analyses of HIV-1 dynamics, release of virus from reservoirs, such as the FDC network, had been considered but not explicitly modelled (Perelson et al. 1996 (Perelson et al. , 1997a Perelson & Nelson 1999) . Here, by using the model of Hlavacek et al. (1999) , we begin to assess the in£uence of FDCs on treatment of HIV-1 infection.
Below, we present a model for HIV-1 dynamics that includes FDCs. It incorporates the model of Hlavacek et al. (1999) and ideas from earlier models for HIV-1 dynamics (McLean et al. 1991; Nowak & Bangham 1996; Bonhoe¡er et al. 1997; Perelson et al. 1997b; Finzi & Siliciano 1998; De Boer & Perelson 1998; Perelson & Nelson 1999) . We then use this model to analyse clinical measurements of cellular and viral dynamics in the blood and LT of a representative patient who was treated with a combination of antiretroviral drugs. Measurements include counts of infected cells in LT (Cavert et al. 1997) , viral RNA on FDC (Cavert et al. 1997 ) and viral RNA in plasma (Notermans et al. 1998b) . Results are compared with those of an earlier analysis for the same patient (Notermans et al. 1998b) , in which neither LT data nor FDCs were considered. This report complements an analysis of Hlavacek et al. (2000) , which includes more patients who participated in the study of Notermans et al. (1998a) .
MODEL
The model is illustrated in ¢gure 1. We consider four types of cells, the vast majority of which we take to be CD4 ‡ T cells in LT (Haase 1999 ): uninfected cells (T), short-lived productively infected cells (T * ), long-lived chronically infected cells (C * ) and latently infected cells carrying viral genomes that are replication competent (L * ). As in earlier work (Perelson & Nelson 1999) , we characterize cellular dynamics with the following equations:
where T, T ¤ , C ¤ and L ¤ represent cell numbers, and V represents the number of free, potentially infectious virions. The rates at which uninfected, productively infected, chronically infected, and latently infected cells die are characterized by ·,¯, · C , and¯L, respectively. Uninfected cells are generated at constant rate l and proliferate according to a logistic growth law (Sachsenberg et al. 1998) , in which p is the rate constant and T c is the carrying capacity. Only T appears in the growth law, as we assume infected cells are a small fraction of the total population. The rates at which uninfected cells enter productive, chronic and latent infection are characterized by k, k C , and k L , respectively. Latently infected cells are activated and enter the productive state of infection with rate constant a. The e¤cacy of treatment with RT inhibitors is represented by e r , with e rˆ0 before treatment and e rˆ1 during treatment with RT inhibitors that are 100% e¡ective. If e rˆ1 during treatment, analytical equations can be found for T, T ¤ , C ¤ and L ¤ as a function of treatment time t; these equations are given in Appendix A.
We consider two types of free virus: potentially infectious virus (V ) and virus modi¢ed by therapy with protease inhibitors (V ). Therapeutic inhibition of HIV-1 protease prevents formation of functional gag and pol gene products, so therapy-modi¢ed virus is non-infectious. Incorporating the recently developed model for binding of HIV-1 to FDC (Hlavacek et al. 1999) into the framework of earlier models for HIV-1 dynamics (Perelson & Nelson 1999) , we obtain the following equations for the dynamics of free and FDC-associated virus:
In these equations, V andV represent virion numbers, R represents the number of free receptors on FDCs, and B i andB i represent the numbers of potentially infectious and non-infectious virions on FDC that are bound to i receptors (a virion can bind up to n receptors). Equation (9) is a conservation law, in which R T represents the total number of receptors in the FDC network. We assume that R T is constant, because antigens, including HIV-1, are retained on the surface of FDCs without signi¢cant internalization (Mandel et al. 1980; Joling et al. 1993; Schmitz et al. 1994) , which suggests that bound receptors on FDCs are not targeted for internalization and that receptor tra¤cking is limited. Parameters in these equations include N, the number of virions released on death of a productively infected cell, º, the rate constant for production of virions by long-lived chronically infected cells, c, the rate constant for clearance of free virus and e p , the e¤cacy of protease inhibitors. free virus Figure 1 . Model for HIV-1 dynamics. The reaction scheme for interaction of HIV-1 with FDC receptors is illustrated elsewhere (Hlavacek et al. 1999 ).
The limitations of this model deserve comment. Equations (7) and (8) are derived by treating virions as multivalent ligands, with (mean) e¡ective valence n, that interact with monovalent receptors (Perelson 1981 (Perelson , 1984 . As discussed elsewhere (Hlavacek et al. 1999) , the receptors are considered to be type 2 complement receptors (CR2), and the binding sites on virions that interact with these receptors are considered to be terminal fragments of complement component C3. Equations of this type have been used previously to model viral attachment to cell surfaces (Wickham et al. 1990 ), but equations (7) and (8) should be understood to idealize the complicated chemistry that governs binding of HIV-1 to FDCs, which involves random deposition of C3 on viral surfaces (Stoiber et al. 1997) , resulting in a distribution of valences, multiple receptor populations on FDCs (Reynes et al. 1985 ) that interact di¡erentially with C3 fragments (Ross & Medof 1985) and enzymatic modi¢cation of C3 (Liszewski et al. 1996) . The simple model that we consider here is appropriate if creation of CR2 binding sites on virions is fast. We consider this a reasonable ¢rst approximation, because factor I, which cleaves C3 to generate terminal C3 fragments (Liszewski et al. 1996) , is closely associated with FDCs (Yamakawa & Imai 1992) . Also, complement receptor type 1 (CR1), a cofactor for factor I (Liszewski et al. 1996) , is abundant on FDCs (Reynes et al. 1985) .
Besides these limitations, we also emphasize that our model only considers the e¡ects of ligand^receptor interactions on the dynamics of FDC-associated virus. The model does not include other processes that might in£uence these dynamics, such as turnover of FDCs, slow growth of the FDC network during therapy (Zhang et al. 1999b) , shedding of iccosomes that bear HIV-1 (Szakal et al. 1988 ) and structural breakdown of virions.
PARAMETER ESTIMATES
We estimate parameters for a representative patient who received triple therapy with a protease inhibitor (ritonavir) and two RT inhibitors (lamivudine and zidovudine) in the study of Notermans et al. (1998a) . This patient is identi¢ed as patient 10 and 20 485 in the substudies of Cavert et al. (1997) and Notermans et al. (1998b) , respectively. Estimates are summarized in table 1.
The densities of HIV-1 RNA in plasma (Notermans et al. 1998b) , FDC-associated HIV-1 RNA in LT and infected mononuclear cells in LT (Cavert et al. 1997) were monitored during treatment. We convert these densities to total body numbers on the basis of 700 g of LT (Haase et al. 1996; Cavert et al. 1997; Zhang et al. 1998) , 15 litres of extracellular £uid (Niyongabo et al. 1999; Kim et al. 1999) and two copies of HIV-1 RNA per virion. Thus, we estimate V 0ˆ4 :1 £ 10 8 , F 0ˆ4 :6 £ 10 10 and T ¤ 0ˆ1 :1 £ 10 8 , the total body numbers of free virions, FDC-associated virions and productively infected cells at the start of therapy, from baseline measurements (Cavert et al. 1997; Notermans et al. 1998b) . To estimate T ¤ 0 , we assume that the baseline density of productively infected cells in LT re£ects mainly the density of short-lived cells.
Several simplifying assumptions aid the analysis. We assume that drugs are 100% e¡ective, i.e., e rˆepˆ1 during treatment. Under this assumption, we need not consider infection, which is characterized by the rate constants k, k C and k L , and we can compare our results with those of an earlier analysis (Notermans et al. 1998b) , in which the same assumption was made. We assume that parameter values are such that L ¤ (t) º 0 throughout the treatment period of interest. Measurements of latently infected cells with replication competent viral genomes indicate that this population is extremely small (Chun et al. 1997) . We examine the case ºˆ0; setting ºˆ0 prevents long-lived cells from contributing to viral dynamics. This allows us to demonstrate that these cells, though they may exist, are not required to explain the decay of HIV-1 during therapy. Hlavacek et al. (1999) determined that the following values are reasonable for parameters that characterize HIV-1 binding to FDC: nˆ20, ¬ˆ1:5 £ 10 ¡10 day
¡1
and k ¡xˆkrˆ8 600 day
. We use these estimates here, but in a sensitivity analysis, we also determine how variation of these parameter values a¡ects our qualitative results.
Estimates of some parameters are obtained from steady-state relationships. The assumption of a pretreatment steady state is supported by a stable plasma viral load before treatment (Notermans et al. 1998b) . To ¢nd N, we use the steady-state forms of equations (5) and (7), which yield the following equation
To ¢nd R T and to characterize the pre-treatment state of FDC receptors and virions on FDCs, we take the following approach. We determine the pre-treatment fraction of receptors that are free, R=R T , by numerically solving
which is derived from equation (9) and the steady-state forms of equations (5) and (7 pre-treatment steady-state value of B i =R T for iˆ1, : : :, n by using
which is also derived from equation (9) and the steadystate forms of equations (5) and (7). We ¢nd R T by using
which is derived from the identity F 0ˆP n iˆ1 B i . Equations (11)^(13) can be combined to determine the baseline values of R and each B i . To ¢nd the value of kT 0 , we use
which is derived from the steady-state form of equation (2) and our assumption that L ¤ (t) º 0. The value of kT 0 is used only in a hypothetical comparision of treatment strategies, in which we assume T (t) º T 0 to simplify the analysis.
We use a nonlinear least-squares ¢tting procedure to determine the values of¯, c, and K x R T (recall that K xˆkx =k ¡x ). With the values of these parameters free to vary, and other parameter values ¢xed or derived from steady-state relationships, the model is ¢t simultaneously to the measured time-courses of decay for plasma virus (Notermans et al. 1998b ) and FDC-associated virus (Cavert et al. 1997) . In this procedure, we numerically integrate the model equations.
RESULTS AND DISCUSSION
(a) Release of virus from FDCs and infected cells
HIV-1 is released from FDCs during therapy. To estimate the magnitude of this release, we compare the measured loss of virus from FDC in a triple-therapy patient (Cavert et al. 1997) with the predicted release of virus from infected cells in this patient, which can be determined from the analysis of Notermans et al. (1998b) . Notermans et al. (1998b) used a conventional model for HIV-1 dynamics, without FDCs, to analyse plasma viral decay in patients who received combination therapy. In our nomenclature, this model, a special case of the one presented here, can be rewritten as follows:
where
The parameter C ¤ 0 is the number of long-lived infected cells at the start of treatment. For the patient of interest, the following parameter values were estimated by Notermans et al. (1998b) Notermans et al. (1998b) and here also, as can be seen by inspecting equations (5) and (6), the rate of virus production by short-and long-lived infected cells is given by N¯T ¤ and ºC ¤ , respectively. Thus, the amount of virus produced by infected cells during therapy at treatment time t can be found from
anḑ
where¸s(t) is the amount produced by short-lived infected cells and¸l(t) is the amount produced by longlived infected cells. Equations (20) and (21) Notermans et al. (1998b) , and estimates of V 0 , T ¤ 0 , and C ¤ 0 , which can be obtained from baseline measurements, we can place an upper bound on the amount of virus produced by infected cells during therapy and we can compare this number with the measured release of virus from FDCs (Cavert et al. 1997) . We have estimated the total numbers of free virions, V 0 , and short-lived infected cells, T (Notermans et al. 1998b) , and the measured density of infected cells in LT at tˆ21 days (Cavert et al. 1997) , a time at which short-lived infected cells can be expected to have largely disappeared. Thus, C ¤ 0ˆ5 :4 £ 10 6 . We can now determine N and º by using the estimated values of A and B (Notermans et al. 1998b ) and equations (18) and (19): Nˆ31 and ºˆ12 day
¡1
. It follows that¸s is less than 3:3 £ 10 9 virions and that¸l is less than 2:0 £ 10 9 virions. Furthermore, total production of virus by infected cells is no more than 5:3 £ 10 9 virions. In comparison, our estimate for the baseline number of virions on FDCs, F 0 , is 4:6 £ 10 10 virions, an order of magnitude larger; Cavert et al. (1997) observed that approximately 90% of this virus is lost from FDCs after three weeks of treatment. It appears that release of HIV-1 from FDC is a signi¢cant process, one that must be considered in models of HIV-1 dynamics. Earlier estimates of parameters that characterize HIV-1 dynamics (e.g.¯and c) should probably be reconsidered, as many of these estimates have been determined on the basis of models without FDCs. , with the latter value based on the analysis of Perelson et al. (1996) . Higher estimates are obtained because cell death and viral clearance are o¡set by release of virus from FDCs. Recent direct measurements of viral clearance (Zhang et al. 1999a; Ramratnam et al. 1999; Igarashi et al. 1999) are consistent with higher estimates of c.
(b) Estimates of¯and c when FDCs are considered
According to the model considered by Notermans et al. (1998b) , as can be seen from equation (17), the ¢rst phase of viral decay should match the death rate of productively infected cells (if c ¾¯), and the second phase of viral decay should match the death rate of long-lived infected cells (if¯¾ · C ). When we consider FDCs, we ¢nd, in contrast, that both phases of viral decay may be signi¢-cantly in£uenced by interactions of HIV-1 with FDCs. The theoretical curves shown in ¢gure 2 are based on ºˆ0, no production of virus by long-lived infected cells. Estimates of¯and c are not signi¢cantly di¡erent nor are ¢ts signi¢cantly improved if, instead of setting ºˆ0, we allow the value of º to vary during the ¢tting procedure. This suggests that long-lived infected cells may play a smaller role than previously expected in determining viral kinetics during therapy. In our analysis, the rate of second-phase decay matches the net rate at which virus is lost from FDCs, as the FDC reservoir is the only source of virus when ºˆ0 and t is much larger than the halflife of short-lived infected cells.
(c) Parameter sensitivity
Estimates of c and¯depend on estimates of other parameters, including the rate constants ¬, k r , and k ¡x and the valence n. However, when we vary the values of these parameters, we consistently estimate values for c andt hat are higher than previous estimates (table 1) . For example, the nominal value of ¬ can be increased or decreased by an order of magnitude without changing the qualitative result that the values of¯and c are higher than those previously estimated by Notermans et al. (1998b) .
(d) Persistence of potentially infectious virus
Another important result of including FDCs in our analysis is the observation that potentially infectious virus can persist during therapy (¢gure 3). This result is obtained even though we assume drugs are 100% e¡ective. The source of the potentially infectious virus is FDCs. Virus present before therapy, a large amount of which is associated with FDCs, is una¡ected by RT and protease inhibitors. This potentially infectious virus is released from FDCs and is present as a signi¢cant fraction of the viral load throughout treatment, even during the second phase of viral decay. This is opposite of what would be expected from earlier models of HIV-1 dynamics, which suggest that second-phase virus is largely non-infectious if drugs are 100% e¡ective. Although some experiments suggest that HIV-1 retained on FDCs remains infectious for long periods (Burton et al. 1997) , additional experiments are required to determine the properties of FDC-associated virus. If this virus is proven to be infectious for long periods, retention of HIV-1 on FDCs may a¡ect the long-term outcome of therapy with currently available drugs, and elimination of FDC-associated virus may be as important as ridding the body of latently infected cells (Chun & Fauci 1999) . In addition to the persistence of potentially infectious virus, ¢gure 3 also illustrates the in£uence of FDCs on viral decay: decay of free virus can be seen to parallel the loss of virus from FDCs.
(e) Comparison of drug regimens Exchange of free and FDC-associated virus is rapid according to our model. This suggests that therapy with only protease inhibitors, such as ritonavir^saquinavir therapy (Cameron et al. 1999) , might have an advantage over drug regimens containing both RT and protease inhibitors in the following respect. Virus produced during protease inhibitor therapy, which will largely lack gag and pol gene products, might compete with potentially infectious virus, present before therapy, for receptors on FDCs. Thus, protease inhibitor therapy might be more e¡ective than RT and protease inhibitor combinations at reducing the infectious titre of virus. A test of this idea is illustrated in ¢gure 4. The decay curves shown in this ¢gure are based on the parameter values used to calculate those in ¢gure 3, but now we have set e rˆ0 (no RT inhibitors). As can be seen by comparing ¢gures 3 and 4, 100% e¡ective therapy with protease inhibitors reduces the level of potentially infectious virus present on FDCs and free in extracellular £uid throughout treatment, though the total viral load (potentially infectious virus plus therapy-modi¢ed non-infectious virus) is higher than with a RT and protease inhibitor combination. Despite this relative improvement, a signi¢cant fraction of virus remains potentially infectious. The advantage of protease inhibitor therapy over RT and protease inhibitor combinations that we have shown here is hypothetical and the level of therapy-modi¢ed virus has yet to be measured in patients, but our results suggest that such measurements might be seriously considered.
CONCLUSION
When we include FDCs in a model for treatment of HIV-1 infection (¢gure 1), we ¢nd that parameters characterizing HIV-1 dynamics,¯and c, must be revised upwards (table 1) . This is because decay of infected cells, characterized by¯, and clearance of free virus, characterized by c, are bu¡ered by release of virus from FDCs. Release of virus from FDCs also suggests an alternative explanation for biphasic decay of virus during therapy, as we have been able to ¢t the viral decay in a triple-therapy patient without including viral production by long-lived infected cells (¢gure 2). The importance of long-lived infected cells in viral dynamics is also challenged by our demonstration that release of virus from FDCs may be an order of magnitude larger than the amount of virus expected to be produced by infected cells during therapy, which we have calculated using equations (20) and (21). These results, which suggest that FDCs play an important role in HIV-1 dynamics, are obtained largely for two reasons: the large amount of virus on FDCs in untreated patients relative to the amount in cells (Cavert et al. 1997) , most of which have a short half-life, and the potential for biphasic release of virus from FDCs during treatment if binding of virus to FDC receptors is reversible and multivalent (Hlavacek et al. 1999) .
We also ¢nd that FDCs may be a source of potentially infectious virus during therapy (¢gure 3), even if drugs are 100% e¡ective. Persistence of virus due to antigen trapping by FDCs suggests that, if virus on FDCs remains infectious (Burton et al. 1997) , therapies should be developed to interfere with the interaction of HIV-1 and FDCs. Such therapies, because second-phase decay of virus parallels loss of virus from FDCs (¢gure 3), may also have the potential to dramatically accelerate viral decay; this potential kinetic e¡ect alone may be su¤cient to motivate the development of therapeutics to block HIV-1 binding to FDCs. Experience suggests that a monovalent ligand that binds to receptors on FDCs may be an e¡ective means for displacing FDC-associated HIV-1 (Goldstein & Wofsy 1996) . The design of such a drug may be feasible, because CR2 is believed to be the principal receptor on FDCs that interacts with HIV-1 (Hlavacek et al. 1999) . Although many cells express CR2, a distinct isoform of this receptor, the long form, is expressed on FDCs (Liu et al. 1997) .
Finally, analysis of the model suggests that treatment with a combination of RT and protease inhibitors may be less e¡ective than treatment with only protease inhibitors, in that the latter strategy allows non-infectious virus produced during treatment to displace potentially infectious virus on FDCs (¢gure 4). Of course, combinations of RT and protease inhibitors may still be more desirable than therapy with protease inhibitors alone for other reasons, such as suppression of drug resistance and the side-e¡ects of potent protease inhibitor regimens. 
